The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis

被引:5
作者
Mecoli, Christopher A. [1 ]
Shah, Ami A. [1 ]
Boin, Francesco [2 ]
Wigley, Fredrick M. [1 ]
Hummers, Laura K. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
PULMONARY ARTERIAL-HYPERTENSION; BRAIN NATRIURETIC PEPTIDE; DIGITAL ULCERS; GROWTH-FACTOR; SCLERODERMA; DISEASE; SURVIVAL; COHORT; VASCULOPATHY; MORTALITY;
D O I
10.1002/art.41265
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective In cross-sectional studies, pulmonary hypertension (PH) and ischemic digital lesions are 2 scleroderma vascular outcomes associated with abnormalities in biomarkers of angiogenesis. The clinical usefulness of these biomarkers is unknown, in part due to lack of data on longitudinal measurement. This prospective longitudinal study was undertaken to evaluate vascular biomarker measurements in patients with systemic sclerosis (SSc) over time. Methods We conducted a prospective cohort study of 300 patients with SSc who were followed up for at least a 5-year period and lacked evidence of PH and/or active ischemic digital lesions at enrollment. Levels of hepatocyte growth factor (HGF), soluble Flt-1 (sFlt-1), soluble endoglin, endostatin, and placental growth factor (PLGF) were obtained at multiple time points and assessed for their ability to predict the development of PH/ischemic digital lesions. Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated. Results Forty-six patients (15%) developed PH and 69 patients (23%) developed an ischemic digital lesion. In time-to-event analyses, the following 3 biomarkers measured at cohort entry were found to be significantly associated with the development of PH: HGF (HR 1.99 [95% CI 1.24-3.17],P= 0.004), sFlt-1 (HR 3.04 [95% CI 1.29-7.14],P= 0.011), and PLGF (HR 2.74 [95% CI 1.32-5.69],P= 0.007). As time approaching PH diagnosis decreased, there was no corresponding increase in any biomarker level. Upon converting each continuous vascular biomarker into a binary variable, a dose-response relationship was observed for the number of elevated biomarkers at cohort entry and the risk of developing PH. With each additional elevated biomarker at cohort entry, there was a 78% increase in the risk of developing PH (HR 1.78 [95% CI 1.2-2.6],P= 0.004). Conclusion These data suggest that molecules involved in angiogenesis reflect vascular perturbation, and that elevations in these biomarkers at first encounter can indicate patients who are at risk of PH development.
引用
收藏
页码:1341 / 1349
页数:9
相关论文
共 36 条
[1]   High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis [J].
Allanore, Y. ;
Avouac, J. ;
Zerkak, D. ;
Meune, C. ;
Hachulla, E. ;
Mouthon, L. ;
Guillevin, L. ;
Meyer, O. ;
Ekindjian, O. G. ;
Weber, S. ;
Kahan, A. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (01) :284-291
[2]   N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers [J].
Allanore, Y ;
Borderie, D ;
Meune, C ;
Cabanes, L ;
Weber, S ;
Ekindjian, OG ;
Kahan, A .
ARTHRITIS AND RHEUMATISM, 2003, 48 (12) :3503-3508
[3]   Defining a Unified Vascular Phenotype in Systemic Sclerosis [J].
Allanore, Yannick ;
Distler, Oliver ;
Matucci-Cerinic, Marco ;
Denton, Christopher P. .
ARTHRITIS & RHEUMATOLOGY, 2018, 70 (02) :162-170
[4]   Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension [J].
Assad, Tufik R. ;
Maron, Bradley A. ;
Robbins, Ivan M. ;
Xu, Meng ;
Huang, Shi ;
Harrell, Frank E. ;
Farber-Eger, Eric H. ;
Wells, Quinn S. ;
Choudhary, Gaurav ;
Hemnes, Anna R. ;
Brittain, Evan L. .
JAMA CARDIOLOGY, 2017, 2 (12) :1361-1368
[5]   Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis [J].
Avouac, Jerome ;
Meune, Christophe ;
Ruiz, Barbara ;
Couraud, Pierre Olivier ;
Uzan, Georges ;
Boileau, Catherine ;
Kahan, Andre ;
Chiocchia, Gilles ;
Allanore, Yannick .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (03) :394-399
[6]   Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis [J].
Chora, Ines ;
Guiducci, Serena ;
Manetti, Mirko ;
Romano, Eloisa ;
Mazzotta, Celestina ;
Bellando-Randone, Silvia ;
Ibba-Manneschi, Lidia ;
Matucci-Cerinic, Marco ;
Soares, Raquel .
AUTOIMMUNITY REVIEWS, 2015, 14 (04) :314-322
[7]  
Chung L, 2016, CLIN EXP RHEUMATOL, V106, P106
[8]   Effect of Bosentan on Systemic Sclerosis-associated Interstitial Lung Disease Ineligible for Cyclophosphamide Therapy: A Prospective Open-label Study [J].
Furuya, Yoshiaki ;
Kuwana, Masataka .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (10) :2186-2192
[9]  
Hachulla E, 2007, J RHEUMATOL, V34, P2423
[10]   Elevated serum placenta growth factor (P/GF) levels in patients with systemic sclerosis: A possible role in the development of skin but not lung fibrosis [J].
Hamaguchi, Yasuhito ;
Hasegawa, Minoru ;
Tanaka, Chihiro ;
Kumada, Sayako ;
Sato, Shinichi ;
Takehara, Kazuhiko ;
Fujimoto, Manabu .
JOURNAL OF DERMATOLOGICAL SCIENCE, 2010, 58 (03) :229-231